Detection of BRAF V600E mutation in glioblastomas (GBMs) is important because of potential therapeutic implications. Still, the relative paucity of these mutations makes molecular detection in all GBMs controversial. In the present study, we analyzed clinical, radiographic and pathologic features of 12 BRAF V600E-mutant GBMs and 12 matched controls from 2 institutions. We found that a majority of BRAF V600E-mutant GBMs displayed a combination of well-circumscribed lesions, large cystic components with thin walls and solid cortical component on MRI, but with some overlap with matched BRAF wildtype controls (p = 0.069). BRAF V600E-mutant GBMs were also apt to gross total resection (83% vs 17%, p = 0.016) and morphologically displayed epithelioid features (83% vs 0%, p < 0.0001). Identification of these clinical, radiographic, and pathologic characteristics should prompt testing for BRAF V600E in IDH-wildtype GBM.

由于潜在的治疗意义，检测胶质母细胞瘤 (GBM) 中的 BRAF V600E 突变很重要。尽管如此，这些突变的相对稀少使得所有 GBM 的分子检测存在争议。在本研究中，我们分析了来自 2 个机构的 12 个 BRAF V600E 突变 GBM 和 12 个匹配对照的临床、放射学和病理特征。我们发现大多数 BRAF V600E 突变 GBM 在 MRI 上显示出界限清楚的病变、具有薄壁的大囊性成分和实性皮质成分的组合，但与匹配的BRAF野生型对照有一些重叠（p  = 0.069）。BRAF V600E 突变的 GBMs 也易于完全切除（83% 对 17%，p = 0.016）和形态学上显示的上皮样特征（83% vs 0%，p  < 0.0001）。这些临床、影像学和病理学特征的识别应促使在 IDH 野生型 GBM 中检测 BRAF V600E。